Cited by 84Alzheimer's disease research and treatmentsPrion Diseases and Protein MisfoldingDementia and Cognitive Impairment Research

Tau prion-like propagation: state of the art and current challenges

Dujardin, Simon, Hyman, Bradley T.·2019·Advances in Experimental Medicine and Biology

Abstract

It has been almost a decade since the hypothesis of active tau protein propagation in Alzheimer's disease and associated tauopathies was formally raised. We view tau propagation as a cascade of events, starting with early tau misfolding, followed by transfer to another, anatomically connected, cell, contaminating in corruption of endogenous tau in the recipient cell through a seeding mechanism of templated misfolding. These mechanisms are very similar to those of other proteinopathies and to ideas about how prion pathologies spread through the brain. Nonetheless, the specific mechanisms underlying each of these steps remains uncertain and is a fertile ground for new experimental approaches potentially requiring new experimental models. We review, here, the state of the art of the research on tau prion-like propagation and we highlight some key challenges to understanding the detailed mechanisms of cell to cell propagation.

Integrity signals

Registry

Crossref · 10.1007/978-981-32-9358-8_23

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Short fibrils and oligomers of tau can transfer from one neuron to another and spread pathology throughout the brain in a prion-like manner.

    “Over the past several years, it has become increasingly evident that short fibrils and oligomers of tau can transfer from one neuron to another and thereby spread pathology throughout the brain in a prion-like manner (4, 5, 6).”

    From MAP2 caps tau fibrils and inhibits aggregation (2023) · cites this paper as [4]

The citation lists haven’t been fetched yet

References 162 · Cited by 84

Authors
Dujardin, S., & Hyman, B. T.
Affiliations
Harvard University (US)
Corresponding author
Hyman, Bradley T.
Venue
Advances in Experimental Medicine and Biology
Published
2019
Volume
1184
Pages
305-325
ISSN
  • 0065-2598 (ISSN-L)
  • 2214-8019
OpenAlex
W3007822979
Cited by
84
References
162
Citations by year
2026: 9 · 2025: 10 · 2024: 11 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 13
FWCI
28.32
Type
book chapter
Language
en
Open access
closed
Locations
  • Advances in experimental medicine and biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (RF1AG059789, P30AG062421)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
tau protein, prion-like propagation, Alzheimer's disease, tauopathy, tau misfolding, cell-to-cell transmission, proteinopathies, experimental model
MeSH terms
Alzheimer Disease, Brain, Humans, Prions, tau Proteins, Tauopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review